Johnson and Johnson announced that the European Commission had approved a supply agreement for 200 million doses of Janssen vaccine.

The contract was signed after exploratory talks with the European Commission.
is in discussions with other stakeholders, including national governments and global organizations, to meet its commitment to supply its alternative vaccines globally.
is provided that the vaccine is safe, effective and approved or authorized by regulatory authorities.
In addition to the agreement with the European Commission, Johnson and Johnson announced plans to allocate up to 500 million doses of vaccine to international fight against the disease in order to meet the company's broader commitment to responding to the new crown outbreak, in order to ensure that vaccines are available in low-income countries.
the vaccine will begin delivery by the middle of next year after regulatory approval or authorization.
Johnson and Johnson is evaluating single-dose options in the large-scale, critical, multi-country Phase 3 trial (ENSEMBLE), which began in September, and plans to launch the second Phase 3 study of a two-dose treatment program later this year.
company has adopted Jansen AdVac technology in the development of ® vaccine.
same technology has also been used by Janssen to develop The Ebola vaccine programme approved by the European Commission and is the basis for its HIV, RSV and Zika candidate vaccines.
, more than 100,000 people have been vaccinated against the ® AdVac vaccine.
.